Ivan Medvedev

Ivan Medvedev

orcid

Research Focus & Metrics

Academic Career Length

8Years (2019-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
15 March 2019 in Terapevticheskii arkhiv
Verified
Journal Article
Open access
VPV I Podzolkov
V I Podzolkov
GMG K Makhnach
G K Makhnach
TITatiana Ivanovna Ishina
Tatiana Ivanovna Ishina
APA B Ponomarev
A B Ponomarev
IMIvan Medvedev
Ivan Medvedev
The article analyzes the diagnosis and treatment of anti-GBM antibody disease (Goodpasture's syndrome) – a rare, severe progressive disease, associated with anti-glomerular basement membrane antibody-induced pulmonary hemorrhage and glomerulonephritis. The main problem of this pathology is late diagnosis, resulted in ineffective treatment. The article provides current information on the epidemiology, etiology and pathogenesis, diagnosis, and treatment of Goodpasture’s syndrome, as well as clinical case of a patient with this rare disease. Keywords: anti-GBM antibody disease, Goodpasture's syndrome, pulmonary-renal syndrome, rapidly progressive glomerulonephritis

14 February 2021 in American Journal of Case Reports
Verified
Journal Article
Closed access
PDF file
IMIvan Medvedev
Ivan Medvedev
VPValery I. Podzolkov
Valery I. Podzolkov
TITatiana I. Ishina
Tatiana I. Ishina
MPMikhail V. Pisarev
Mikhail V. Pisarev
BACKGROUND:Eosinophilic granulomatosis with polyangiitis (EGPA) is a rare and severe progressive disease with multiple clinical manifestations and organ damage. Usually, it requires long-term monitoring of the state of many organs due to the gradual character of its manifestations. CASE REPORT:We report a case of a long-term follow-up of a patient with eosinophilic granulomatosis with polyangiitis with emphasis on specific clinical features in this patient. A 64-year-old man was being followed up for 10 years. The initial diagnosis was allergic bronchial asthma; however, as new clinical signs and symptoms developed, the diagnosis of EGPA became obvious. A positive treatment response was seen, mainly manifested as reduced polyneuropathy. Meanwhile, bronchial asthma remained uncontrolled and bronchiectasis and Klebsiella pneumoniae colonization developed despite the combination treatment with prednisolone and methotrexate. Furthermore, the patient suffered a cerebral ischemic infarction. During the last hospital admission, severe uncontrolled bronchial asthma complicated with pneumonia resulted in the patient’s death. CONCLUSIONS:This clinical case shows the gradual development of EGPA with multiple-organ involvement, including respiratory manifestations and peripheral and central nervous system damage. Immunosuppressive treatment combined with complications of EGPA could have contributed to severe pneumonia development and death of the patient.

8 May 2023 in Cardiovascular Therapy and Prevention
Verified
Journal Article
Open access
PDF file
VPV. I. Podzolkov
V. I. Podzolkov
ABAnna E. Bragina
Anna E. Bragina
IMIvan Medvedev
Ivan Medvedev
MVM. V. Vetluzhskaya
M. V. Vetluzhskaya
AAA. A. Abramova
A. A. Abramova
ASA. V. Sutulova
A. V. Sutulova
Failure to achieve blood pressure targets and insufficient control are important cardiology problems that remain relevant despite well-defined and generally available modern algorithms for the treatment of hypertension (HTN) and the availability of effective antihypertensive drugs. The level of hypertension control in Russia remains quite low and is 14,1% for men and 30,9% for women. The generally recognized most important factor determining the low blood pressure control is non-compliance with antihypertensive therapy, which, in turn, determines the high percentage of uncontrolled HTN among patients. The review discusses the most common causes of low adherence to treatment. Particular attention is paid to the doctor’s ability to remove barriers to adherence and errors in the choice of therapy, including insufficient prescribing of fixed-dose combinations. The review presents a modern view on the significance of combined antihypertensive therapy. Atten­tion is focused on fixed-dose combinations of antihypertensives, the use of which significantly increases adherence to therapy, and the unique properties and effectiveness of lisinopril, amlodipine and indapamide are described.

15 August 2019 in Terapevticheskii arkhiv
Verified
Journal Article
Open access
VPV I Podzolkov
V I Podzolkov
NDN A Dragomiretskaya
N A Dragomiretskaya
ODO Ts Dambaeva
O Ts Dambaeva
SAS T Auvinen
S T Auvinen
IMIvan Medvedev
Ivan Medvedev
A high serum vitamin B12 level (hypercobalaminemia) is a underestimated anomaly. Clinically, it can be paradoxically accompanied by signs of deficiency, which are related to defects in tissue uptake of vitamin B12. The increase in the level of serum cobalamin occurs mainly in serious diseases that require early diagnosis: hemoblastosis, liver and kidney diseases, etc. This review presents data on the metabolism of vitamin B12 and the potential significance of increasing its level as a marker for the early diagnosis of these diseases. Keywords: hypervitaminosis B12, hypercobalaminemia, hemoblastosis, liver diseases

30 June 2023 in Cardiovascular Therapy and Prevention
Verified
Journal Article
Open access
PDF file
VPV. I. Podzolkov
V. I. Podzolkov
ATA. I. Tarzimanova
A. I. Tarzimanova
AAA. A. Abramova
A. A. Abramova
MVM. V. Vetluzhskaya
M. V. Vetluzhskaya
IMIvan Medvedev
Ivan Medvedev
ILIrakli Loriya
Irakli Loriya
The article presents the main mechanisms of development of lipid metabolism disorders and endothelial dysfunction in patients with hypertension (HTN) and type 2 diabetes (T2D), and their contribution to cardiovascular events. Modern approaches to the treatment of hypertension and dyslipidemia in people with type 2 diabetes are considered from the standpoint of the latest clinical guidelines, focusing on fixed-dose combinations as a means of an integrated approach to managing risk factors in comorbid patients. Data are presented on the efficacy and safety of fixed-dose combination of lisinopril, amlodipine and rosuvastatin in patients with hypertension and T2D.

22 April 2024 in Russian Journal of Cardiology
Verified
Journal Article
Open access
PDF file
VPV. I. Podzolkov
V. I. Podzolkov
NDN. A. Dragomiretskaya
N. A. Dragomiretskaya
IMIvan Medvedev
Ivan Medvedev
ATA. V. Tolmacheva
A. V. Tolmacheva
AKA. V. Kosareva
A. V. Kosareva
ISI. I. Shvedov
I. I. Shvedov
Aim. To evaluate the impact of community-acquired pneumonia (CAP) on the levels of cardiac biomarkers and long-term survival rate in patients with heart failure (HF). Material and methods. The prospective observational single-center study included 132 patients (73 men, 59 women); mean age — 72,3±12,1 years, consecutively hospitalized at Clinical Hospital № 4 of the I. M. Sechenov First Moscow State Medical University with decompensated heart failure in the period from March 2018 to December 2019. The main (n=40) and comparison group (n=92) included patients with and without clinical and CT signs of CAP, respectively. Results. Patients with HF and CAP and HF without CAP were comparable in sex, age, and severity of HF. CAP in most patients met the criteria for non-severe pneumonia (average CURB-65 score — 1,55±0,73). The levels of N-terminal probrain natriuretic peptide (NT-proBNP) in patients with HF with CAP (1188,9 [439; 2493] pg/ml) were insignificantly higher than in patients with HF without CAP (839,6 [413; 1900]) pg/ml (p>0,05). A similar pattern was noted for the soluble growth stimulation expressed gene 2 (sST2) (30,85 [12,8; 59,6] ng/ml vs 22,8 [15,2; 44,7] ng/ml, p>0,05). The haptoglobin level in patients with CAP was significantly lower (732 [315; 1312] ng/l), compared to the group without CAP (1270 [902; 2022] ng/l, p=0,0022). No differences in the concentrations of galectin-3, copeptin and hepcidin were detected. The one-year mortality rate of patients who underwent CAP was 27,3%, and without CAP — 7,2% (p<0,001), while the three-year mortality rate was 44,9% and 21,4%, respectively (p=0,0004). Elevated levels of NT-proBNP and sST2, along with age over 75 years and left ventricular ejection fraction <40%, are additional factors of poor prognosis in patients with HF and CAP. Conclusion. CAP in patients with HF does not have a significant effect on most cardiac biomarkers, but significantly worsens the prognosis. Independent factors of unfavorable prognosis in patients with HF and CAP are age over 75 years, left ventricular ejection fraction <40%, increased NT-proBNP and sST2 levels.